We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 417

Amicus briefs on biosimilar patent litigation

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 23 2015

Amgen has appealed the district court decision denying its motion for a preliminary injunction to keep Sandoz' biosimilar version of Neupogen off

Apotex has standing despite Benicar patent disclaimer

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 9 2015

In Apotex Inc. v. Daiichi Sankyo, Inc., the Federal Circuit held that Apotex has standing to seek a declaratory judgment that it does not infringe

Waiting on Sequenom

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 7 2015

As I write this there’s a voice in my head saying, “Be careful what you wish for!” but it has been five months since Sequenom was argued at the

No collateral challenge of patent application revival

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 31 2015

In Exela Pharma Sciences, LLC v. Lee, the Federal Circuit held that the USPTO's decision to revive a patent application &8220;is not subject to

Federal Circuit finds disclaimer based on “object of invention” language

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 25 2015

The Federal Circuit's recent decision in Pacing Technologies, LLC v. Garmin International, Inc. (No. 2014-1396) provides patent litigators with a

Judge finds biosimilar patent procedures optional

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 23 2015

Judge Seeborg of the U.S. District Court for the Northern District of California issued an order inAmgen, Inc. v. Sandoz, Inc., ruling that the

Federal Circuit limits patent exhaustion doctrine for complementary technology

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 11 2015

In its 2013 decision in Keurig, Inc. v. Sturm Foods, Inc., the Federal Circuit held that a purveyor of coffee cartridges did not infringe Keurig’s

The Remicade biosimilar patent dispute

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 10 2015

While Sandoz has grabbed the biosimilar headlines for being the first company to have a product approved under the Biologics Price Competition and

Patent eligibility under Alice: reliance on lack of routine or conventional use

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 3 2015

Federal courts have continued to wrestle with the standard for patent eligibility under 35 U.S.C. 101 set by the Supreme Court's ruling in

Federal Circuit upholds Patent Term Adjustment deduction for IDS filed after Restriction Requirement

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 2 2015

In Gilead Sciences, Inc. v. Lee, the Federal Circuit upheld the USPTO's interpretation of the Patent Term Adjustment (PTA) statute as permitting the